Anti-CD7 CAR T-cell therapy (Yake Biotechnology)

N/A

Report date: 2022/02/17 14:38:20

Base Information

Drug NameAnti-CD7 CAR T-cell therapy (Yake Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD7
TargetsT-cell antigen CD7
Therapy Area/IndicationsAutoimmune DiseasesBone Marrow Failure DisordersAnemia, Aplastic +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co LtdShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesBone Marrow Failure DisordersAnemia, Aplastic +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A